The FDA has appointed Jeremy Walsh as its first chief artificial intelligence officer to improve internal IT systems and streamline the medical product review process. With a background in AI and cloud projects from Booz Allen Hamilton, Walsh's role supports Commissioner Martin Makary's initiative to modernize drug approvals, which have often taken over a decade. The FDA recently completed its first AI-assisted scientific review and is developing cderGPT, a specialized AI tool for drug reviewers, with plans to implement generative AI across all centers by June. Commissioner Makary emphasized the necessity of action in leveraging AI to enhance efficiency in the agency's operations.
